U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H11N3O3S
Molecular Weight 229.2576
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LAMIVUDINE

SMILES

c1cn([C@]2([H])CS[C@]([H])(CO)O2)c(nc1=N)O

InChI

InChIKey=JTEGQNOMFQHVDC-NKWVEPMBSA-N
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

HIDE SMILES / InChI
Molecular Formula C8H11N3O3S
Molecular Weight 229.2576
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00709 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2df7349c-f5d7-47b5-d29b-1b6b31985591

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. The most common reported adverse reactions in adults are headache, nausea, malaise and fatigue. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.

CNS Activity

CNS Penetrant
2344
Curator's Comment:: Known to be CNS penetrant in rat, guinea pig. Human data not available. http://www.ncbi.nlm.nih.gov/pubmed/9593963 http://www.ncbi.nlm.nih.gov/pubmed/18042828 http://www.ncbi.nlm.nih.gov/pubmed/12766261

Originator

Approval Year

1995
184
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
 2.0 nM [IC50]
Inhibitor
7728
 3.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
EPIVIR

Approved Use

EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Launch Date

1.10108161E12
Primary
Approved
8043
EPIVIR

Approved Use

EPIVIR-HBV is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation

Launch Date

1.10108161E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.3 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29150845
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LAMIVUDINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.4 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf
150 mg 2 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LAMIVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.4 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29150845
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LAMIVUDINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.53 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf
150 mg 2 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LAMIVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.9 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29150845
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LAMIVUDINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Other AEs: Malaise and fatigue, Ear, nose and throat infection...
Other AEs:
Malaise and fatigue (25%)
Ear, nose and throat infection (17%)
Cough (8%)
Headache (17%)
Nausea and vomiting (8%)
Ear, nose and throat infection (8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Other AEs: Coughing, Diarrhea...
Other AEs:
Coughing (6 patients)
Diarrhea (9 patients)
Abdominal discomfort (2 patients)
Nausea and vomiting (1 patient)
Malaise and fatigue (6 patients)
Headache (6 patients)
Disorder sleep (4 patients)
Cognitive disorders (2 patients)
Oral ulceration (2 patients)
Oral lesion (2 patients)
Muscle pain (3 patients)
Arthralgia (1 patient)
Temperature regulation disorder (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Other AEs: Malaise and fatigue, Cough...
Other AEs:
Malaise and fatigue (27%)
Cough (27%)
Temperature regulation disorder NOS (27%)
Nausea and vomiting (9%)
Ear, nose and throat infection (18%)
Ear disorder (9%)
Pharyngitis (18%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Other AEs: Headache, Malaise and fatigue...
Other AEs:
Headache (35%)
Malaise and fatigue (27%)
Chills & fever (10%)
Nausea (33%)
Diarrhea (18%)
Nausea and vomiting (13%)
Decreased appetite (10%)
Abdominal pain (9%)
Abdominal cramps (6%)
Dyspepsia (5%)
Neuropathy (12%)
Insomnia disorder (11%)
Dizziness (10%)
Depressive disorders (9%)
Nasal disorders NEC (20%)
Cough (18%)
Skin rash (9%)
Musculoskeletal pain (12%)
Myalgia (8%)
Arthralgia (5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Ear, nose and throat infection 17%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Headache 17%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Malaise and fatigue 25%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Cough 8%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Ear, nose and throat infection 8%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Nausea and vomiting 8%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Arthralgia 1 patient
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Nausea and vomiting 1 patient
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Abdominal discomfort 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Cognitive disorders 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Oral lesion 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Oral ulceration 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Temperature regulation disorder 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Muscle pain 3 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Disorder sleep 4 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Coughing 6 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Headache 6 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Malaise and fatigue 6 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Diarrhea 9 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Ear, nose and throat infection 18%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Pharyngitis 18%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Cough 27%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Malaise and fatigue 27%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Temperature regulation disorder NOS 27%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Ear disorder 9%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Nausea and vomiting 9%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Chills & fever 10%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Decreased appetite 10%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Dizziness 10%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Insomnia disorder 11%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Musculoskeletal pain 12%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Neuropathy 12%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Nausea and vomiting 13%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Cough 18%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Diarrhea 18%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Nasal disorders NEC 20%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Malaise and fatigue 27%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Nausea 33%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Headache 35%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Arthralgia 5%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Dyspepsia 5%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Abdominal cramps 6%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Myalgia 8%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Abdominal pain 9%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Depressive disorders 9%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Skin rash 9%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1467
inhibitor
1604
inhibitor
1702

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OATP1B1
733

OATP1B3
657

MATE2
251

OCT3
140

BCRP
643

P-gp
1330

OCT1
480

OCT2
594
MATE1
127

MATE2
91

OCT1
302

OCT2
316

P-gp
1400

BCRP
515

CYP
236
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1648
 no
CYP2D6
1738
 no
CYP3A4
1772
 no
MATE2
251
 no
OATP1B1
748
 no
OATP1B3
666
 no
BCRP
713
 weak to no
OCT3
140
 weak to no
P-gp
1514
 weak to no
OCT1
495
 yes
OCT2
595
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
236
 not signifiicant
BCRP
515
 yes
MATE1
127
 yes
MATE2
91
 yes
OCT1
302
 yes
OCT2
316
 yes
P-gp
1400
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63577
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63577
ChemicalBook
CB1290608
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1290608
MolPort
MolPort-002-507-347
https://www.molport.com/shop/molecule-link/MolPort-002-507-347
Selleck Chemicals
Lamivudine(Epivir)
http://www.selleckchem.com/products/Lamivudine(Epivir).html
ZINC
ZINC000000012346
http://zinc15.docking.org/substances/ZINC000000012346
eMolecules
1987423
https://www.emolecules.com/cgi-bin/more?vid=1987423
eMolecules
2726078
https://www.emolecules.com/cgi-bin/more?vid=2726078
eMolecules
31588897
https://www.emolecules.com/cgi-bin/more?vid=31588897
PubMed

PubMed

TitleDatePubMed
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.
1999 Oct 1
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
2000
Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report.
2000 Apr 27
Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.
2000 Aug
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
2000 Aug
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
2000 Aug
Synthesis and anti-HIV evaluation of new 2',3'-dideoxy-3'-thiacytidine prodrugs.
2000 Jul
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
2000 Jul
Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
2000 Jul
Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
2000 Jul
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
2000 Jul
Management of hepatitis B in China.
2000 Jul
Profound suppression of hepatitis B virus replication with lamivudine.
2000 Jul
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
2000 Jul
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
2000 Jul 4
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
2000 Jun 10
Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy.
2000 Jun 16
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
2000 Nov
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
2000 Nov
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
2000 Oct
Synthesis and antiviral activity of oxaselenolane nucleosides.
2000 Oct 19
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.
2000 Sep
Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.
2000 Sep 15
Antiviral beta-L-nucleosides specific for hepatitis B virus infection.
2001
Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore.
2001 Apr
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.
2001 Apr
Anti-HBV specific beta-L-2'-deoxynucleosides.
2001 Apr-Jul
Outcome of liver transplantation for hepatitis B: report of a single center's experience.
2001 Aug
Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant.
2001 Feb
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.
2001 Feb
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
2001 Feb
Antiviral L-nucleosides specific for hepatitis B virus infection.
2001 Jan
From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
2001 Jan 24-31
[Treatment of chronic viral hepatitis B with lamivudine].
2001 Jan 27
Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
2001 Jul
Nelfinavir in expanded postexposure prophylaxis causing acute hepatitis with cholestatic features: two case reports.
2001 Jun
Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.
2001 Jun
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
2001 Jun
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
2001 Jun
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.
2001 Jun 29
The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host.
2001 Mar
Efavirenz-induced acute eosinophilic hepatitis.
2001 May
Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity.
2001 May
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
2001 May
Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.
2001 May-Jun
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.
2001 Nov 19
Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.
2001 Sep
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
2001 Sep
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
2001 Sep
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
2001 Sep 1
Patents

Patents

05905082
3
US5047407
4

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Pediatric dose should be calculated on body weight (kg) and should not exceed 300 mg daily. Dosage of this product is for HIV-1 and not for HBV
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:24 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:24 UTC 2021
Record UNII
2T8Q726O95
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LAMIVUDINE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
TEMIXYS COMPONENT LAMIVUDINE
Common Name English
EPIVIR
Brand Name English
LAMIVUDINE [EP MONOGRAPH]
Common Name English
4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]
Systematic Name English
EMTRICITABINE IMPURITY C [WHO-IP]
Common Name English
KIVEXA COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINUM [WHO-IP LATIN]
Common Name English
GR-109714X
Code English
COMBIVIR COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE
Brand Name English
TRIZIVIR COMPONENT LAMIVUDINE
Brand Name English
VIROLAM
Common Name English
LAMIVUDINE [WHO-IP]
Common Name English
NSC-760061
Code English
LAMIVUDINE [USP-RS]
Common Name English
3TC
Code English
TELURA COMPONENT OF LAMIVUDINE
Common Name English
LAMIVUDINE [WHO-DD]
Common Name English
LAMIVUDINE COMPONENT OF TRIUMEQ
Brand Name English
LAMIVUDINE COMPONENT OF TRIZIVIR
Brand Name English
LAMIVUDINE COMPONENT OF DUTREBIS
Brand Name English
GR 109714X
Code English
LAMIVUDINE COMPONENT OF DELSTRIGO
Brand Name English
LAMIVUDINE COMPONENT OF COMBIVIR
Common Name English
DELSTRIGO COMPONENT LAMIVUDINE
Brand Name English
LAMIVUDINE COMPONENT OF TEMIXYS
Common Name English
LAMIVUDINE [ORANGE BOOK]
Common Name English
LAMIVUDINE TEVA
Brand Name English
LAMIVUDINE [INN]
Common Name English
ZEFFIX
Brand Name English
LAMIVUDINE [HSDB]
Common Name English
LAMIVUDINE [JAN]
Common Name English
LAMIVUDINE TEVA PHARMA B.V.
Brand Name English
(-)-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE
Systematic Name English
LAMIVUDINE [EMA EPAR]
Common Name English
LAMIVUDINE COMPONENT OF EPZICOM
Common Name English
BCH 189, (-)-
Code English
TRIUMEQ COMPONENT LAMIVUDINE
Brand Name English
LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA
Brand Name English
LAMIVUDINE [MART.]
Common Name English
EPZICOM COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINE [USAN]
Common Name English
LAMIVUDINE [VANDF]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-, (2R-CIS)-
Common Name English
LAMIVUDINE [USP MONOGRAPH]
Common Name English
LAMIVUDINE [EP]
Common Name English
LAMIVUDINE [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175462
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AR04
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR05
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AR02
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
NCI_THESAURUS C97452
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS LAMIVUDINE TEVA PHARMA B.V. (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AR05
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS KIVEXA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AR11
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR02
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR11
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/ZID)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR16
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
NDF-RT N0000175656
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS ZEFFIX (AUTHORIZED: HEPTATIS B, CHRONIC)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR24
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR12
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR07
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
NDF-RT N0000009947
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS EPIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/STA)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
LIVERTOX 538
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR01
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR13
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AR04
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS TRIUMEQ (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AR01
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ATC J05AF05
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AR07
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS TRIZIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/ZID)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS LAMIVUDINE TEVA (AUTHORIZED: HEPATITIS B, CHRONIC)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
EMA ASSESSMENT REPORTS DUTREBIS (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
WHO-VATC QJ05AF05
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
Code System Code Type Description
INN
6908
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
RXCUI
68244
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY RxNorm
CAS
134678-17-4
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
FDA UNII
2T8Q726O95
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
LACTMED
Lamivudine
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LAMIVUDINE
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY Description: A white or almost white powder.Solubility: Soluble in water; sparingly soluble in methanol R; practically insoluble in acetone R. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Lamivudine should be kept in a well-closed container, protected from light. Additional information: Lamivudine may exhibit polymorphism. Definition: Lamivudine contains not less than 97.0% and not more than 103.0% of C8H11N3O3S, calculated with reference to the dried substance.
MESH
D019259
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL141
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
NCI_THESAURUS
C1471
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
HSDB
7155
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
EPA CompTox
134678-17-4
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
USP_CATALOG
1356836
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
LAMIVUDINE
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
DRUG BANK
DB00709
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
EVMPD
SUB08392MIG
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
MERCK INDEX
M6672
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY Merck Index
PUBCHEM
60825
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
DRUG CENTRAL
1539
Created by admin on Fri Jun 25 21:02:24 UTC 2021 , Edited by admin on Fri Jun 25 21:02:24 UTC 2021
PRIMARY
Related Record Type Details
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
INHIBITOR->TARGET ORGANISM
Structure of LAMIVUDINE METHANOL SOLVATE
SALT/SOLVATE -> PARENT
Structure of LAMIVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of LAMIVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 POLYMERASE
TARGET -> INHIBITOR
HEPATITIS B VIRUS
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of LAMIVUDINE SULFOXIDE, (S)-
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of TROXACITABINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 5-(4-AMINO-2-OXOPYRIMIDIN-1(2H)-YL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID, CIS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTOSINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE SULFOXIDE, (R)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE SULFOXIDE, (S)-
IMPURITY -> PARENT
Structure of LAMIVUDINE SULFOXIDE, (R)-
IMPURITY -> PARENT
Structure of URACIL
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE, (+/-)-TRANS-
IMPURITY -> PARENT
Structure of 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDINE-2,4(1H,3H)-DIONE, (2R,5S)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of URACIL
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity F. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity F (uracil) about 0.36.
Structure of EMTRICITABINE
PARENT -> IMPURITY
Structure of 5-(4-AMINO-2-OXOPYRIMIDIN-1(2H)-YL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID, CIS-
IMPURITY -> PARENT
Structure of SALICYLIC ACID
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity C. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity C (salicylic acid) about 2.6. In the chromatogram obtained with solution (1): - the area of any peak corresponding to impurity C is not greater than that of the principal peak in the chromatogram obtained with solution (3) (0.1%).
Structure of 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDINE-2,4(1H,3H)-DIONE, (2R,5S)-
IMPURITY -> PARENT
Structure of SALICYLIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTOSINE
IMPURITY -> PARENT
Structure of CYTOSINE
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity F. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity E (cytosine) about 0.31. In the chromatogram obtained with solution (1):- the area of any individual peak corresponding to impurity E, when multiplied by a correction factor of 0.6, is not greater than the area of the peak in the chromatogram obtained with solution (2) (0.1%).
Structure of LAMIVUDINE, (+)-CIS-
IMPURITY -> PARENT
Structure of TROXACITABINE
IMPURITY -> PARENT
Structure of LAMIVUDINE, (+/-)-TRANS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of URACIL
IMPURITY -> PARENT
Structure of LAMIVUDINE, (+)-CIS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of SALICYLIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LAMIVUDINE SULFOXIDE, (S)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
Structure of LAMIVUDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Intercellular
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966